Retatrutide and trizepatide constitute a novel class of medications that bind to both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These multifunctional receptor agonists display promising therapeutic potential in the management of type 2 diabetes. Retatrutide, a once-weekly subcutaneous inje